| Catalog No. | VK515016 |
| Host species | Human |
| Species reactivity | Influenza A virus |
| Form | Liquid |
| Storage buffer | 0.01M PBS, pH 7.4. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Clonality | Monoclonal |
| Isotype | IgG1, lambda |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Target | HA/Hemagglutinin |
| Purification | Protein A/G purified from cell culture supernatant. |
| Endotoxin level | Please contact the lab for this information. |
| Expression system | Mammalian Cells |
| Accession | P03455 |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternative name | CR-6261, CR6261, 1393659-46-5 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
Research Grade Diridavumab
Overview
Description
Diridavumab, the alternative name, CR6261, is a human monoclonal antibody directed against influenza A hemagglutinin. The CR6261 antibody was first discovered by the Scripps Institute and Crucell, a Dutch biopharmaceutical company, and later developed by Janssen Pharmaceutical Companies of Johnson & Johnson under the trade name diridavumab. Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of Diridavumab in Japanese Healthy Participants).
Images
 Bioactivity |
SEC-HPLC detection for Research Grade Diridavumab. |
 SDS-PAGE |
SDS-PAGE for Research Grade Diridavumab. |